AbbVie, Lambic Therapeutics Sign Multi-Year AI Drug Discovery Deal

AbbVie Inc. (ABBV) announced on September 21, 2026, a multi-year collaboration with Lambic Therapeutics to accelerate discovery and development of small molecule therapies in immunology, neuroscience and oncology, using AI-driven drug discovery. The financial terms of the pact were not disclosed in the initial announcement. Lambic Therapeutics is a clinical-stage life sciences and technology company. The partnership expands AbbVie's pipeline in three core therapeutic areas.